Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Stu... von Gentilini, Chiara, Hilbers, Urte, Hartung, Goetz, Lange, Thoralf, Kliem, Constanze, Hegenbart, Ute, Zeis, Mathias, Huppert, Volker, Glass, Bertram, Uhrberg, Marcus, Schmitz, Norbert, Thiel, Eckhard, Niederwieser, Dietger W., Uharek, Lutz

Volltext

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial von Merz, Maximilian, Salwender, Hans, Haenel, Mathias, Mai, Elias K, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W, Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Hillengass, Jens, Raab, Marc S, Schurich, Baerbel, Munder, Markus, Schmidt-Wolf, Ingo G H, Gerecke, Christian, Lindemann, Hans-Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan, Goldschmidt, Hartmut

Volltext

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial von Merz, Maximilian, Salwender, Hans, Haenel, Mathias, Mai, Elias K, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W, Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Hillengass, Jens, Raab, Marc S, Schurich, Baerbel, Munder, Markus, Brossart, Peter, Gerecke, Christian, Lindemann, Hans-Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan, Goldschmidt, Hartmut

Volltext

BMP7 aberrantly induced in the psoriatic epidermis instructs inflammation-associated Langerhans cells von Borek, Izabela, Köffel, René, Feichtinger, Julia, Spies, Melanie, Glitzner-Zeis, Elisabeth, Hochgerner, Mathias, Sconocchia, Tommaso, Krump, Corinna, Tam-Amersdorfer, Carmen, Passegger, Christina, Benezeder, Theresa, Tittes, Julia, Redl, Anna, Painsi, Clemens, Thallinger, Gerhard G., Wolf, Peter, Stary, Georg, Sibilia, Maria, Strobl, Herbert

Volltext

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Anal... von Goldschmidt, Hartmut, Duerig, Jan, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Haenel, Mathias, Blau, Igor Wolfgang, Hose, Dirk, Jauch, Anna, Schurich, Baerbel, Neben, Kai, Seckinger, Anja, Huegle-Doerr, Barbara, Merz, Maximilian, Munder, Markus, Lindemann, Walter, Zeis, Matthias, Gerecke, Christian, Schmidt-Wolf, Ingo GH, Weisel, Katja, Scheid, Christof, Salwender, Hans

Volltext

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG von Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Kunz, Christina, Salwender, Hans, Haenel, Mathias, Merz, Maximilian, Mai, Elias Karl, Hose, Dirk, Schurich, Baerbel, Munder, Markus, Schmidt-Wolf, Ingo, Gerecke, Christian, Lindemann, Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan, Jauch, Anna, Goldschmidt, Hartmut

Volltext

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma von Merz, Maximilian, Salwender, Hans-Juergen, Haenel, Mathias, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W., Scheid, Christof, Mai, Elias Karl, Hose, Dirk, Schurich, Bärbel, Munder, Markus, Brossart, Peter, Gerecke, Christian, Lindemann, Hans Walter, Zeis, Matthias, Weisel, Katja C., Duerig, Jan, Goldschmidt, Hartmut

Volltext

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial von Merz, Maximilian, Salwender, Hans, Hänel, Mathias, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W., Scheid, Christof, Mai, Elias Karl, Hose, Dirk, Schurich, Baerbel, Munder, Markus, Schmidt-Wolf, Ingo GH, Gerecke, Christian, Lindemann, Hans Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan, Goldschmidt, Hartmut

Volltext

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial von Moohialdin, Mabast, Salwender, Hans, Bertsch, Uta, Duerig, Jan, Kunz, Christina, Hielscher, Thomas, Zorn, Markus, Haenel, Mathias, Blau, Igor Wolfgang, Hose, Dirk, Schurich, Baerbel, Neben, Kai, Seckinger, Anja, Munder, Markus, Lindemann, Walter, Zeis, Matthias, Gerecke, Christian, Schmidt-Wolf, Ingo GH, Weisel, Katja, Scheid, Christof, Goldschmidt, Hartmut

Volltext

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma von Merz, Maximilian, Salwender, Hans, Haenel, Mathias, Mai, Elias K, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W, Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Hillengass, Jens, Raab, Marc S, Schurich, Baerbel, Munder, Markus, Schmidt-Wolf, Ingo G.H, Gerecke, Christian, Lindemann, Hans-Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan, Goldschmidt, Hartmut

Volltext bestellen